A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
- Registration Number
- NCT00147485
- Lead Sponsor
- Pfizer
- Brief Summary
AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.
- Detailed Description
The study was prematurely discontinued due to the inability of the compound to adequately differentiate from other treatment options in the clinical endpoint and necessary product profile on April 13, 2007. Safety profile was not the reason that led to the discontinuation of the program.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
- Advanced solid tumors or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition
- Adequate blood cell counts, kidney function and liver function and and ECOG score of 0 or 1.
Exclusion Criteria
- Prior high-dose chemotherapy requiring hemapoietic stem cell rescue
- Previous radiation therapy to >25% of the bone marrow
- Active or unstable cardiac disease or history of heart attack within 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 AG-024322 -
- Primary Outcome Measures
Name Time Method To test the safety of AG-024322 when taken by people who have cancer To find the AG-024322 dose that should be used in future clinical trials that will study effectiveness To assess how the human body handles blood concentrations of AG-024322
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Philadelphia, Pennsylvania, United States